Retroperitoneal Fibrosis
Welcome,         Profile    Billing    Logout  
 3 Companies   1 Product   1 Product   3 Mechanisms of Action   0 Trials   3 News 
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial completion, Trial primary completion date:  Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) -  Jan 8, 2015   
    P1/2,  N=30, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Enrollment closed:  Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) -  Oct 17, 2013   
    P1/2,  N=30, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014 Recruiting --> Active, not recruiting
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    New P1/2 trial:  Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) -  Apr 23, 2012   
    P1/2,  N=30, Active, not recruiting,